Next, the study showed that the AMPK agonist metformin and the mTOR inhibitors INK128 and rapamycin could reduce the percentage of M-MDSCs in mice with pristane-induced lupus and TLR7- and IFN-α-induced BM differentiation into MDSCs in vitro. This evidence concerns the gene MTOR and systemic lupus erythematosus.